In a randomized controlled trial, 41 chronic hepatitis B virus carriers were allocated, by opening numbered computerized randomization envelopes, to receive recombinant interferon-a2A at three different doses: 2.5; 5.0, and 10.0 mU per m2. Thirty-two patients received treatment (6 for 3 months, 26 f
Effects of HTLV III virus infection on replication, severity of liver disease and response to interferon in chronic hepatitis B virus carriers
✍ Scribed by Canon, Stephen
- Book ID
- 122582263
- Publisher
- Elsevier Science
- Year
- 1985
- Tongue
- English
- Weight
- 70 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Twelve of 32 patients lost HBeAg and DNA polymerase from their serum after completing antiviral therapy with interferon and/or adenine arabinoside. Three lost serum HBsAg as well. Loss of corresponding viral markers from hepatic tissue was also seen. There was improvement in symptoms, hepatic tests,
In patients with chronic hepatitis C, the influence of the genetic heterogeneity of the hepatitis C virus (HCV) on the progression of liver disease and on the responsiveness to interferon therapy is a matter of controversy. In this study we evaluated the genetic complexity of HCV by singlestrand con